ML18096B130: Difference between revisions
Jump to navigation
Jump to search
StriderTol (talk | contribs) (Created page by program invented by StriderTol) |
StriderTol (talk | contribs) (Created page by program invented by StriderTol) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 2: | Line 2: | ||
| number = ML18096B130 | | number = ML18096B130 | ||
| title = 06-27843-02 608390 Bristol-Myers Squibb Company PRI (F.A.) | | title = 06-27843-02 608390 Bristol-Myers Squibb Company PRI (F.A.) | ||
| release date = 07/23/2018 | |||
| package contents = {{Adams package content | | package contents = {{Adams package content | ||
| number = ML18194A517 | |||
| issue date = 06/27/2018 | |||
| title = Bristol-Myers Squibb Company; Review of Financial Assurance Submittal, Mail Control No. 608390 | |||
| author name = Lawyer D | |||
| author affiliation = NRC/RGN-I/DNMS/CRDB | |||
| addressee name = Pooler J R | |||
| addressee affiliation = Bristol-Myers Squibb Co | |||
| docket = 03029266 | |||
| license number = 06-27843-02 | |||
| contact person = | |||
| case reference number = 608390 | |||
| document type = Financial Assurance Document, Letter | |||
| page count = 2 | |||
}}{{Adams package content | |||
| number = ML18096B133 | | number = ML18096B133 | ||
| issue date = 02/13/2018 | | issue date = 02/13/2018 | ||
| title = | | title = Bristol-Myers Squibb Company PRI, Form 10-K for the Fiscal Year Ended December 31, 2017 | ||
| author name = | | author name = | ||
| author affiliation = Bristol-Myers Squibb Co, US Securities & Exchange Commission (SEC) | | author affiliation = Bristol-Myers Squibb Co, US Securities & Exchange Commission (SEC) | ||
| Line 20: | Line 35: | ||
| number = ML18096B132 | | number = ML18096B132 | ||
| issue date = 03/30/2018 | | issue date = 03/30/2018 | ||
| title = | | title = Bristol-Myers Squibb Company PRI, Financial Assurance Action Letter Dtd March 30, 2018 | ||
| author name = Pooler J | | author name = Pooler J | ||
| author affiliation = Bristol-Myers Squibb Co | | author affiliation = Bristol-Myers Squibb Co | ||
| addressee name = | | addressee name = | ||
Latest revision as of 18:42, 25 January 2020
| Date released: 07/23/2018 | Download: ML18096B130 |
|---|---|
| ML18194A517 | |
| Person / Time | |
|---|---|
| Site: | 03029266 |
| Issue date: | 06/27/2018 |
| From: | Lawyer D NRC/RGN-I/DNMS/CRDB |
| To: | Pooler J R Bristol-Myers Squibb Co |
| References | |
| 608390 | |
| Download: ML18194A517 (2) | |
| ML18096B133 | |
| Person / Time | |
|---|---|
| Site: | 03029266 |
| Issue date: | 02/13/2018 |
| From: | Bristol-Myers Squibb Co, US Securities & Exchange Commission (SEC) |
| To: | Division of Nuclear Materials Safety I |
| References | |
| 608390 | |
| Download: ML18096B133 (171) | |
| ML18096B132 | |
| Person / Time | |
|---|---|
| Site: | 03029266 |
| Issue date: | 03/30/2018 |
| From: | Pooler J Bristol-Myers Squibb Co |
| To: | Division of Nuclear Materials Safety I |
| References | |
| 608390 | |
| Download: ML18096B132 (23) | |